Takeda Pharmaceutical Company Limited
SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES
Last updated:
Abstract:
Methods of administering isolated anti-CD38 antibodies subcutaneously are disclosed. The methods provide an effective treatment for autoimmune diseases and cancers, including hematologic diseases. Also disclosed are unit dosage forms for the anti-CD38 antibodies.
Status:
Application
Type:
Utility
Filling date:
27 Mar 2019
Issue date:
18 Feb 2021